Cargando…
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show complex karyotype (CK), and these cases include a relatively high proportion of cases of therapy-related myeloid neoplasms and TP53 mutations. We aimed to evaluate the clinicopathologic features of outcome of 299 AML a...
Autores principales: | Weinberg, Olga K., Siddon, Alexa, Madanat, Yazan F., Gagan, Jeffrey, Arber, Daniel A., Dal Cin, Paola, Narayanan, Damodaran, Ouseph, Madhu M., Kurzer, Jason H., Hasserjian, Robert P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092405/ https://www.ncbi.nlm.nih.gov/pubmed/35073573 http://dx.doi.org/10.1182/bloodadvances.2021006239 |
Ejemplares similares
-
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023) -
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
por: Loke, Justin, et al.
Publicado: (2023) -
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
por: Bennett, Joshua, et al.
Publicado: (2023) -
AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
por: Klever, Marius-Konstantin, et al.
Publicado: (2023) -
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)